Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $148.9 million.

  • Artiva Biotherapeutics' Liabilities and Shareholders Equity fell 34.01% to $148.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $719.1 million, marking a year-over-year change of. This contributed to the annual value of $209.6 million for FY2024, which is 99.38% up from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Liabilities and Shareholders Equity stood at $148.9 million, which was down 12.12% from $169.4 million recorded in Q2 2025.
  • Artiva Biotherapeutics' Liabilities and Shareholders Equity's 5-year high stood at $225.6 million during Q3 2024, with a 5-year trough of $75.9 million in Q2 2024.
  • Over the past 3 years, Artiva Biotherapeutics' median Liabilities and Shareholders Equity value was $169.4 million (recorded in 2025), while the average stood at $160.8 million.
  • The largest annual percentage gain for Artiva Biotherapeutics' Liabilities and Shareholders Equity in the last 5 years was 123.14% (2025), contrasted with its biggest fall of 34.01% (2025).
  • Artiva Biotherapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $105.1 million in 2023, then soared by 99.38% to $209.6 million in 2024, then tumbled by 34.01% to $148.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $148.9 million in Q3 2025, compared to $169.4 million in Q2 2025 and $191.3 million in Q1 2025.